Xeris Biopharma Holdings Inc(XERS) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | RUT | P/E | - | EPS (ttm) | -0.1 | Insider Own | 5.39% | Shs Outstand | 173.6M | Perf Week | -10.61% |
| Market Cap | 1.40B | Forward P/E | 21.43 | EPS next Y | 1041.73% | Insider Trans | -3.46% | Shs Float | 172.5M | Perf Month | -8.58% |
| Enterprise Value | 1.57B | PEG | - | EPS next Q | 0.04 | Inst Own | 59.67% | Short Float | 5.06% | Perf Quarter | 14.31% |
| Income | -0.02B | P/S | 4.17 | EPS this Y | -1284.91% | Inst Trans | 1.47% | Short Ratio | 4.64 | Perf Half Y | 33.86% |
| Sales | 0.34B | P/B | - | EPS next 5Y | - | ROA | -4.6% | Short Interest | 8.73M | Perf YTD | -2.29% |
| Book/sh | -0.06 | P/C | 11.49 | EPS past 3/5Y | - | ROE | - | 52W High | -23.91% ($10.08) | Perf Year | -1.79% |
| Cash/sh | 0.67 | P/FCF | 25.12 | Sales past 3/5Y | 38.33% 70.2% | ROIC | -8.19% | 52W Low | 46.1% ($5.25) | Perf 3Y | 265.24% |
| Dividend Est. | - | EV/EBITDA | 31.7 | EPS Y/Y TTM | 54.68% | Gross Margin | 83.34% | Volatility(W/M) | 5.46% 4.13% | Perf 5Y | 187.27% |
| Dividend TTM | - | EV/Sales | 4.67 | Sales Y/Y TTM | 36.33% | Oper. Margin | 10.91% | ATR (14) | 0.36 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 1.02 | EPS Q/Q | -1387.6% | Profit Margin | -5.12% | RSI (14) | 33.12 | Recom | 1.43 |
| Dividend Gr. 3/5Y | - | Current Ratio | 1.45 | Sales Q/Q | 28.74% | SMA20 | -9.79% ($8.5) | Beta | 0.7 | Target Price | $12.29 |
| Payout | - | Debt/Eq | - | Earnings | 2026/8/6 | SMA50 | -8.76% ($8.41) | Rel Volume | 1.03 | Prev Close | $7.71 |
| Employees | 435 | LT Debt/Eq | - | EPS/Sales Surpr. | -1587.6% 0.98% | SMA200 | 8.67% ($7.06) | Avg Volume(3M) | 1.88M | Price | $7.67 |
| IPO | 2018/6/21 | Option/Short | Yes/Yes | Trades | 13170 | Volume | 1,945,144 | Change | -0.52% |
Company
XERS is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.
💉 Xeris Biopharma (XERS) is a US specialty pharmaceutical company focused on endocrine, diabetes, and rare disease areas. Leveraging its proprietary formulation technology that makes injectable medicines stable and ready-to-use at room temperature, the company markets three commercial products: Gvoke, a treatment for severe hypoglycemia; Keveyis, a treatment for primary periodic paralysis; and Recorlev, a treatment for endogenous Cushing's syndrome.
Over the past 1 year, roughly in the middle
24% below its 1-year high.
XERS has weak earning power
10.91% of revenue is kept as operating profit.
Tap to view numbers
Growth has stalled
Earnings are expected to grow by -1284.9% this year.
Tap to view numbers
The price looks about right
Trading at - times earnings.
Tap to view numbers
Results came in about as expected
Slight tendency to beat estimates
Tap to view numbers
The outlook is positive
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have paid off
Would have changed by +265.2% if bought 5 years ago.
Tap to view numbers
Dividends are hard to expect
This stock does not pay dividends
Ownership looks stable
Institutions hold 59.7%.
Tap to view numbers
Multiple ETFs hold this stock
Buying this ETF gives you exposure to this stock as well.
XPH 0.01%
PILL 0.01%
LFSC 0.01%
BBC 0.01%
SGRW 0.01%It ranks #4 in the industry
Based on market cap of $1B.
XERS $1B PER -
TAK $58B PER -
TEVA $42B PER 61.1
HLN $41B PER 19.0
FAQ
What kind of company is XERS?
XERS belongs to the Healthcare sector and operates in the Drug Manufacturers - Specialty & Generic industry.
What is the market cap of XERS?
The market cap of XERS is approximately $1.4B, ranking 2,382 within its sector.
What is the 52-week high and low for XERS?
XERS has recorded a 52-week high of $10.08 and a low of $5.25.
